Lv3
310 积分 2022-03-12 加入
Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies
2天前
已完结
Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis
2个月前
已完结
Current Status in Rechallenge of Immunotherapy
2个月前
已关闭
Neoadjuvant and Adjuvant Treatment for Early-Stage Resectable Non-small Cell Lung Cancer (NSCLC): Consensus Recommendations from the International Association for the Study of Lung Cancer (IASLC)
2个月前
已完结
How Do I Manage Refractory Invasive Pulmonary Aspergillosis
8个月前
已关闭
How Do I Manage Refractory Invasive Pulmonary Aspergillosis
8个月前
已关闭
Risk of COVID-19-associated pulmonary aspergillosis: time for a nuanced approach to antifungal prophylaxis?
8个月前
已完结
How Do I Manage Refractory Invasive Pulmonary Aspergillosis
8个月前
已关闭
How Do I Manage Refractory Invasive Pulmonary Aspergillosis
8个月前
已关闭
Phase 2 Study of the PD-1 Inhibitor Serplulimab Plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma
10个月前
已完结
皖公网安备34019202002308
